Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test

被引：22

作者：

Sajjadi, Elham ^{[1
,2
]}

Guerini-Rocco, Elena ^{[1
,2
]}

De Camilli, Elisa ^{[2
]}

Pala, Oriana ^{[2
]}

Mazzarol, Giovanni ^{[2
]}

Venetis, Konstantinos ^{[2
]}

Ivanova, Mariia ^{[2
]}

Fusco, Nicola ^{[1
,2
]}

机构：

[1] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[2] European Inst Oncol IRCCS, IEO, Div Pathol, Milan, Italy

来源：

FRONTIERS IN MOLECULAR BIOSCIENCES | 2023年 / 10卷

关键词：

breast cancer; HER2; HER2-low; pathology; precision medicine; immunohistochemistry; in situ hybridization; INTRATUMORAL HETEROGENEITY; REPRODUCIBILITY; QUANTIFICATION; EXPRESSION;

D O I：

10.3389/fmolb.2023.1176309

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, without gene amplification) tumors is challenged by methodological and analytical variables that might influence the sensitivity and reproducibility of HER2 testing. To open all possible therapeutic opportunities for HER2-low breast cancer patients the implementation of more accurate and reproducible testing strategies is mandatory. Here, we provide an overview of the existing barriers that may trouble HER2-low identification in breast cancer and discuss practical solutions that could enhance HER-low assessment.

引用

页数：6

共 39 条

[1] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation [J].

Ahn, Soomin ;

Woo, Ji Won ;

Lee, Kyoungyul ;

Park, So Yeon .

JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2020, 54 (01) :34-44

[2] The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization [J].

Angerilli, Valentina ;

Galuppini, Francesca ;

Pagni, Fabio ;

Fusco, Nicola ;

Malapelle, Umberto ;

Fassan, Matteo .

DIAGNOSTICS, 2021, 11 (02)

[3] Refining the definition of HER2-low class in invasive breast cancer [J].

Atallah, Nehal M. ;

Toss, Michael S. ;

Green, Andrew R. ;

Mongan, Nigel P. ;

Ball, Graham ;

Rakha, Emad A. .

HISTOPATHOLOGY, 2022, 81 (06) :770-785

[4] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[5] Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations [J].

Bianchi, S. ;

Caini, S. ;

Paglierani, M. ;

Saieva, C. ;

Vezzosi, V. ;

Baroni, G. ;

Simoni, A. ;

Palli, D. .

PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (02) :477-485

[6] Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification [J].

Brunelli, Matteo ;

Manfrin, Erminia ;

Martignoni, Guido ;

Miller, Keith ;

Remo, Andrea ;

Reghellin, Daniela ;

Bersani, Samantha ;

Gobbo, Stefano ;

Eccher, Albino ;

Chilosi, Marco ;

Bonetti, Franco .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (05) :678-682

[7] Guidance for laboratories performing molecular pathology for cancer patients [J].

Cree, Ian A. ;

Deans, Zandra ;

Ligtenberg, Marjolijn J. L. ;

Normanno, Nicola ;

Edsjo, Anders ;

Rouleau, Etienne ;

Sole, Francesc ;

Thunnissen, Erik ;

Timens, Wim ;

Schuuring, Ed ;

Dequeker, Elisabeth ;

Murray, Samuel ;

Dietel, Manfred ;

Groenen, Patricia ;

Van Krieken, J. Han .

JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (11) :923-931

[8] Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low [J].

Fan, Pinchao ;

Xu, Kun .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01)

[9] Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue [J].

Fernandez, Aileen, I ;

Liu, Matthew ;

Bellizzi, Andrew ;

Brock, Jane ;

Fadare, Oluwole ;

Hanley, Krisztina ;

Harigopal, Malini ;

Jorns, Julie M. ;

Kuba, M. Gabriela ;

Ly, Amy ;

Podoll, Mirna ;

Rabe, Kimmie ;

Sanders, Mary Ann ;

Singh, Kamaljeet ;

Snir, Olivia L. ;

Soong, T. Rinda ;

Wei, Shi ;

Wen, Hannah ;

Wong, Serena ;

Yoon, Esther ;

Pusztai, Lajos ;

Reisenbichler, Emily ;

Rimm, David L. .

JAMA ONCOLOGY, 2022, 8 (04) :607-610

[10] Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC) [J].

Fusco, Nicola ;

Rizzo, Antonio ;

Costarelli, Leopoldo ;

Santinelli, Alfredo ;

Cerbelli, Bruna ;

Scatena, Cristian ;

Macri, Ettore ;

Pietribiasi, Francesca ;

D'Amati, Giulia ;

Sapino, Anna ;

Castellano, Isabella .

PATHOLOGICA, 2022, 114 (02) :104-110

← 1 2 3 4 →